Subscribe
shutterstock_1732246315_repelsteeltje
Repelsteeltje / Shutterstock.com
29 September 2020AmericasSarah Morgan

Appeals court sides with Pfizer, Merck KGaA in $5bn suit

The US Court of Appeals for the Federal Circuit has sided with EMD  Serono and Pfizer over the invalidation of a multiple sclerosis (MS) drug patent, in a defeat for biotech company Biogen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
MSD secures victory before English court
20 October 2020   The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
MSD secures victory before English court
20 October 2020   The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

More on this story

Biotechnology
Biogen loses another battle over MS drug patent
21 September 2020   In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
Asia-Pacific
Australian court issues mixed vaccine patent ruling
15 October 2020   In a mixed decision for Merck Sharp Dohme, the Federal Court of Australia has concluded that the pharmaceutical company is infringing one patent owned by Wyeth, but that two other Wyeth patents are invalid.
Big Pharma
MSD secures victory before English court
20 October 2020   The English High Court has concluded that Merck Sharp Dohme is not infringing a patent owned by Pfizer through the sale of its pneumococcal conjugate vaccine.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers